Russell Investments Group Ltd. reduced its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 35.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,527,592 shares of the company's stock after selling 835,667 shares during the period. Russell Investments Group Ltd. owned approximately 0.08% of Kenvue worth $32,614,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of KVUE. Janus Henderson Group PLC increased its holdings in shares of Kenvue by 40.6% in the 3rd quarter. Janus Henderson Group PLC now owns 219,576 shares of the company's stock worth $5,080,000 after purchasing an additional 63,400 shares in the last quarter. Integrated Wealth Concepts LLC raised its stake in Kenvue by 12.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 35,022 shares of the company's stock worth $810,000 after acquiring an additional 3,962 shares during the period. Quarry LP raised its position in shares of Kenvue by 311.3% during the 3rd quarter. Quarry LP now owns 3,241 shares of the company's stock valued at $75,000 after purchasing an additional 2,453 shares during the period. Quantinno Capital Management LP lifted its position in shares of Kenvue by 168.4% in the third quarter. Quantinno Capital Management LP now owns 81,314 shares of the company's stock valued at $1,881,000 after acquiring an additional 51,016 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC lifted its holdings in Kenvue by 27.4% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 61,804 shares of the company's stock worth $1,430,000 after purchasing an additional 13,304 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Kenvue Stock Performance
Kenvue stock traded up $0.23 during trading hours on Friday, hitting $22.10. 13,221,710 shares of the stock traded hands, compared to its average volume of 16,918,224. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a market capitalization of $42.25 billion, a price-to-earnings ratio of 41.71, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm's 50 day moving average price is $22.65 and its 200-day moving average price is $22.40.
Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.71%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio is currently 154.72%.
Analyst Ratings Changes
KVUE has been the topic of a number of research analyst reports. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Canaccord Genuity Group upped their price objective on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. UBS Group dropped their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Piper Sandler raised their price target on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Finally, Redburn Atlantic started coverage on shares of Kenvue in a report on Thursday. They set a "neutral" rating and a $23.50 price objective on the stock. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $24.42.
Read Our Latest Analysis on Kenvue
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
